FilippiMAmatoMPCentonzeD, et al. Early use of high-efficacy disease‑modifying therapies makes the difference in people with multiple sclerosis: An expert opinion. J Neurol2022;269(10):5382–5394.
2.
TolaymatSSharmaKKagziY, et al. Anti-CD20 monoclonal antibody (mAb) therapy and colitis: A case series and review. Mult Scler Relat Disord2023;75:104763.
3.
SandbornWJColombelJFEnnsR, et al. Natalizumab induction and maintenance therapy for Crohn’s disease. N Engl J Med2005;353(18):1912–1925.
4.
BarbutiEPCBorrielloGPetraccaM. Addressing autoimmune comorbidities in multiple sclerosis: A case report of ulcerative colitis remission in a patient treated with cladribine tablets. Mult Scler J2025.
5.
DaubySDDHansenILommersE, et al. Cladribine monotherapy in a patient with coexisting Crohn’s disease and multiple sclerosis. Mult Scler J2025.
6.
DuchiniAYounossiZMSavenA, et al. An open-label pilot trial of cladibrine (2-cholordeoxyadenosine) in patients with primary sclerosing cholangitis. J Clin Gastroenterol2000;31(4):292–296.
7.
ComiGCookSGiovannoniG, et al. Effect of cladribine tablets on lymphocyte reduction and repopulation dynamics in patients with relapsing multiple sclerosis. Mult Scler Relat Disord2019;29:168–174.
